logo
Plus   Neg
Share
Email

Cara Therapeutics: IDMC Recommends To Proceed KALM-1 Trial As Planned

Cara Therapeutics, Inc. (CARA) announced the completion of an interim statistical analysis of its pivotal KALM-1 Phase 3 trial of KORSUVA Injection in hemodialysis patients with moderate-to-severe chronic kidney disease-associated pruritus. The company said, based on the recommendation of the Independent Data Monitoring Committee, the trial will continue as planned with no changes to the original enrollment target of 350 patients.

Derek Chalmers, CEO of Cara Therapeutics, said: "We are very pleased with the IDMC recommendation that the KALM-1 trial proceed as planned with no modifications, and we look forward to completing the study and reporting top-line data in the first half of this year."

The Phase 3 U.S. study is a multicenter, randomized, double-blind, placebo-controlled 12-week treatment trial (with a 52-week open label extension phase) that is designed to evaluate the safety and efficacy of 0.5 mcg/kg CR845/difelikefalin injection in 350 hemodialysis patients with moderate-to-severe pruritus.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Tesla has been ordered to stop work at the site of its proposed $4-billion Gigafactory in the German state of Brandenburg due to environmental concerns, according to reports. The proposed factory was going to be Tesla's first Gigafactory in Europe and its fourth in the world. On Saturday, a German court reportedly ordered the company to stop cutting down trees on the 300-hectare site. Dairy Farmers of America (DFA) on Tuesday inked an agreement with bankrupt diary company Dean Foods Co. to become the Stalking Horse Bidder, in a court-supervised sale process, to acquire a substantial portion of Dean's assets and business. While filing for bankruptcy in November last year, Dean Foods had said it was in advanced discussions with the farmer-owned Cooperative. Franklin Resources, Inc. (BEN), a global investment management organization operating as Franklin Templeton, agreed Tuesday to acquire Legg Mason, Inc. (LM) for $50.00 per share of common stock in an all-cash transaction of $4.5 billion. Franklin Templeton will also assume approximately $2 billion...
Follow RTT
>